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Idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS) are clinically and genetically heterogeneous dis-
orders caused by a deﬁciency of gonadotrophin-releasing hormone (GnRH). Mutations in three genes—KAL1, GNRHR and
FGFR1—account for 15–20% of all causes of IHH/KS. Nearly all mutations are point mutations identiﬁed by traditional
PCR-based DNA sequencing. The relatively new method of multiplex ligation-dependent probe ampliﬁcation (MLPA) has been
successful for detecting intragenic deletions in other genetic diseases. We hypothesized that MLPA would detect intragenic dele-
tions in 15–20% of our cohort of IHH/KS patients. Fifty-four IHH/KS patients were studied for KAL1 deletions and 100 were
studied for an autosomal panel of FGFR1, GNRH1, GNRHR, GPR54 and NELF gene deletions. Of all male and female subjects
screened, 4/54 (7.4%) had KAL1 deletions. If only anosmic males were considered, 4/33 (12.1%) had KAL1 deletions. No deletions
were identiﬁed in any of the autosomal genes in 100 IHH/KS patients. We believe this to be the ﬁrst study to use MLPA to identify
intragenic deletions in IHH/KS patients. Our results indicate 12% of KS males have KAL1 deletions, but intragenic deletions of
the FGFR1, GNRH1, GNRHR, GPR54 and NELF genes are uncommon in IHH/KS.
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Introduction
Idiopathic hypogonadotropic hypogonadism (IHH) is comprised of
absent puberty, infertility and low serum gonadotrophins in the
absence of a pituitary tumor. IHH is due to impaired gonadotrophin
releasing hormone (GnRH) release/action or gonadotrophin secretion.
Kallmann syndrome (KS) consists of IHH with anosmia. KS appears
to be the result of impairment of GnRH and olfactory neuron
migration from the olfactory placode to the hypothalamus (Bhagavath
and Layman, 2007).
Mutations in genes involved in GnRH neuron migration (KAL1
and FGFR1), as well as those expressed in either the hypothalamus
or pituitary, including GNRHR, NROB1, GPR54, LEP, LEPR
and PCSK1 account for the molecular etiology of 15–20% of all
IHH/KS patients (Hardelin, 2001; de Roux, 2005; Pitteloud et al.,
2006; Bhagavath and Layman, 2007; Seminara, 2007). Three
genes—KAL1, GNRHR and FGFR1—account for the majority of
causative mutations. The molecular basis for most IHH/KS cases,
however, remains unknown. Digenic disease has been reported in
two families with FGFR1 and either a GNRHR or a NELF mutation
(Pitteloud et al., 2007).
Most mutations identiﬁed in genetic diseases, including IHH/
KS, are point mutations and small deletions/duplications detected
by PCR-based DNA sequencing (Kim et al., 2008). PCR based
sequencing may not detect heterozygous gene deletions,
however, since the remaining normal allele will be ampliﬁed.
Therefore, it is possible that a substantial number of mutations
remain undiagnosed.
Multiplex ligation-dependent probe ampliﬁcation (MLPA) is a rela-
tively new method for detecting copy number variations in genomic
sequences (Schouten et al., 2002). MLPA involves overnight hybrid-
ization of adjacent primer pairs to the individual exons of multiple
target genes simultaneously, followed by a ligation reaction of the
probe pairs, which then serve as a template for multiplex PCR. Each
ligated probe has a varying length of ‘stuffer’ sequences that
produce different sized fragments for resolution based upon size
(Schouten et al., 2002). Since all probes have identical primer
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of all genes being studied.
Heterozygous intragenic deletions have been found in 15–20%
of patients with cystic ﬁbrosis (Audrezet et al., 2004), deafness
(Del Castillo et al., 2003) and breast/ovarian cancer (Hogervorst
et al., 2003) who did not have point mutations in the corresponding
genes. We hypothesized that a similar percentage of IHH/KS patients
would have heterozygous deletions of autosomal genes (FGFR1,
GNRH1, GNRHR, GPR54 or NELF) and/or hemizygous KAL1
gene deletions, deletions which would be missed by the traditional
PCR-based sequencing methods. Additionally, since KAL1 has a
pseudogene homolog on the Y chromosome, this may complicate
the DNA sequencing analysis (Del Castillo et al., 1992).
Materials and Methods
Patients
One-hundred and twelve probands with IHH/KS were studied by MLPA
(Table I). The diagnosis of IHH was based upon criteria published pre-
viously—absent/impaired puberty by age  17 in girls and age  18 in boys,
low serum gonadotrophins, no evidence of a pituitary tumor and otherwise
normal pituitary function (Crowley et al., 1985; Bhagavath et al., 2006). All
males had total testosterone ,100 ng/dl (normal 300–1100 ng/dl), and all
females had hypoestrogenic amenorrhea. Complete IHH was deﬁned as
absent breast development in females and testicular size  3 ml in males
(Bhagavath et al., 2006). Incomplete IHH suggested the presence of prior
steroid production and was deﬁned as breast development of Tanner  2i n
females and testis size .3 ml in males. Patient characteristics are shown in
Table I. The Medical College of Georgia Human Assurance Committee
approved this study; each patient signed informed consent.
Fifty-four patients were studied for the presence of KAL1 deletions (KAL1
kit) and 100 IHH/KS patients were studied for deletions of an autosomal panel
of FGFR1, GNRH1, GNRHR, GPR54 and NELF genes (KAL2 kit). We esti-
mated that we needed a sample size of 50 for study of KAL1 gene deletions,
since the prevalence of mutations is about 6% in anosmic males (Bhagavath
et al., 2007).The samplesize for theautosomal genepanel (KAL2kit) was esti-
mated to be 100. The prevalence of FGFR1 mutations in both normosmic
IHH and KS is about 10% (Pitteloud et al., 2006), whereas GNRHR mutations
occurin 3–4%of normosmicIHH (Bhagavath et al., 2005).This sampleshould
allow detection if they occur in this frequency. The prevalence of GNRH1,
NELF and GPR54 mutations in IHH and KS is currently unknown, but is prob-
ably low. By screening 100 patients, we could determine if the prevalence
was at least 1%.
KAL1 gene deletions were studied in 45 males and nine females. Since
KAL1 mutations have been exclusively identiﬁed in anosmic/hyposmic
patients, the majority of patients studied (40/54) were anosmic/hyposmic. All
patients were randomly selected from available DNA samples without regard
to prior mutation analysis from our large IHH/KS cohort.
Molecular analysis/MLPA
DNA was extracted from white blood cells in all IHH/KS using standard
methods. MLPA was performed in patients according to Schouten (Schouten
et al., 2002; Hogervorst et al., 2003). A total of 125 ng of DNA was hybridized
overnight to the probe sets of the commercially available kits. The P132 KAL1
kit (MRC Holland, Amsterdam, Netherlands) contains 34 probe pairs for all 14
KAL1 exons and control sequences for other regions on Xp, Xq and Yq11. The
P133 KAL2 kit contains 39 probe pairs covering the following exons of auto-
somal genes: GNRH1 (exons 1–3 of 4 exons), GNRHR (exons 1–3 of 3
exons), GPR54 (exons 1, 4 and 5 of 5 exons), FGFR1 (1–3, 5, 6, 8,10,13,14
and 18 of 18 exons) and NELF (exons 5, 11 and 15 of 16 exons). These
probes also include control sequences on chromosomes 1–3, 6, 11, 15–17,
19, 20 and Y.
Following hybridization, a ligationreaction was performedwhichserved as a
template for 35 cycles of multiplex PCR using universal primers. PCR products
were analyzed on an ABI 310 autoanalyzer using the Gene Scan program and
data were evaluated using Genotyper 2.0 (both from Applied Biosystems,
Foster City, CA, USA). Peak areas for each exon were converted into an
Excel ﬁle and the relative copy number of each fragment was compared to
the same fragments from 2 to 3 controls. MLPA was repeated at least three
times for patients with putative deletions. Deletions were conﬁrmed by PCR
and DNA sequencing (Bhagavath et al., 2007).
Results
Using MLPA for the KAL1 gene, deletions were identiﬁed in 4/54
(7.4%) patients and in 4/40 (10%) of anosmic/hyposmic patients
(Table II). When only anosmic males were considered, KAL1 del-
etions were present in 4/33 (12.1%). Three whole gene deletions
were detected, as indicated by absence of peaks for each exon
Table I. Classiﬁcation of patients by gene(s) tested.
KAL1 Kit KAL2 Kit KAL1&KAL2 Kits Total Patients Studied
All subjects studied n ¼ 54 All subjects studied n ¼ 100 Studied with both kits n ¼ 42 Individual subjects n ¼ 112
(154–42)
Male 45 Male 72 Male 38 Male 79
Anosmic/Hypos 33 Anosmic/Hypos 37 Anosmic/Hypos 26 Anosmic/Hypos 44
Normosmic 12 Normosmic 18 Normosmic 12 Normosmic 18
Unknown 0 Unknown 17 Unknown 0 Unknown 17
Complete IHH 13 Complete IHH 15 Complete IHH 10 Complete IHH 18
Incomplete IHH 20 Incomplete IHH 19 Incomplete IHH 18 Incomplete IHH 21
Unknown 12 Unknown 38 Unknown 10 Unknown 40
Female 9 Female 28 Female 4 Female 33
Anosmic/Hypos 7 Anosmic/Hypos 7 Anosmic/Hypos 3 Anosmic/Hypos 11
Normosmic 2 Normosmic 10 Normosmic 1 Normosmic 11
Unknown 0 Unknown 11 Unknown 0 Unknown 11
Complete IHH 3 Complete IHH 7 Complete IHH 2 Complete IHH 8
Incomplete IHH 2 Incomplete IHH 6 Incomplete IHH 0 Incomplete IHH 8
Unknown 4 Unknown 15 Unknown 2 Unknown 17
Totals 54 Totals 100 Totals 42 Totals 112
Anosmic/Hypos 40 Anosmic/Hypos 44 Anosmic/Hypos 29 Anosmic/Hypos 55
Normosmic 14 Normosmic 28 Normosmic 13 Normosmic 29
Unknown 0 Unknown 28 Unknown 0 Unknown 28
Complete IHH 16 Complete IHH 22 Complete IHH 12 Complete IHH 26
Incomplete IHH 22 Incomplete IHH 25 Incomplete IHH 18 Incomplete IHH 29
Unknown 16 Unknown 53 Unknown 12 Unknown 57
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368(Fig. 1). All three whole gene deletions were conﬁrmed by the absence
of bands by PCR. In one of these patients, deletion of exons 1–13 had
previously been identiﬁed (Bhagavath et al., 2007); however, DNA
sequencing of exon 14 was consistent with pseudogene sequence,
thereby conﬁrming the whole gene deletion by MLPA. One patient
had an exon 4 deletion (Fig. 1) which, upon DNA sequencing,
revealed a 3 bp deletion (TGT) of codon 164, deleting a Cys
(Cys164del) rather than the deletion of the entire exon. No heterozy-
gous/homozygous deletions were identiﬁed in the FGFR1, GNRH1,
GNRHR, GPR54 or NELF genes in 100 IHH/KS patients.
Discussion
The genetic basis of IHH/KS has been identiﬁed in 15–20% of
patients, most commonly in KAL1, GNRHR or FGFR1 genes
(Bhagavath and Layman, 2007). KAL1 mutations have been identiﬁed
in anosmic males—approximately 5% of KS males without a family
history and 30–70% of those with clear X-linked recessive inheritance
(Bhagavath et al., 2007). GNRHR mutations cause autosomal reces-
sive IHH in 3–5% of IHH patients, all of whom are normosmic
(Bhagavath et al., 2005). Interestingly, FGFR1 mutations occur in
10% of anosmic or normosmic patients (Pitteloud et al., 2006).
Nearly all mutations in these genes are point mutations or small del-
etions/insertions. In contrast, only a very few gross deletions been
identiﬁed in IHH/KS candidate genes. Available prevalence studies
likely underestimate IHH/KS gene deletions as traditional PCR-based
DNA sequencing is unable to detect heterozygous gene deletions.
Therefore, it is possible that a substantial number of mutations
remain undiagnosed. Using MLPA, heterozygous intragenic deletions
have been found in 15–20% of patients with cystic ﬁbrosis (Audrezet
et al., 2004), deafness (Del Castillo et al., 2003) and breast/ovarian
cancer (Hogervorst et al., 2003) who did not have point mutations.
MLPA is an effective technique used to detect genomic deletions
and duplications (Schouten et al., 2002). If probe pairs for individual
exons are utilized, MLPA can successfully determine the relative
copy number of all exons within gene/genes simultaneously. MLPA
has gained acceptance in genetic diagnostic laboratories due to its sim-
plicity,relatively lowcost and capacityfor reasonablyhigh throughput
analysis.MLPAhasavarietyofapplicationsinadditiontodetectionof
deletions/duplications.Other importantusesinclude aneuploidydetec-
tion (Gerdes et al., 2005), analysis of DNA methylation (Procter et al.,
2006), relative mRNA quantiﬁcation (Wehner et al., 2005), chromoso-
mal characterization of cell lines and tissue samples (Wilting et al.,
2006) and the detection of polymorphisms (Volikos et al., 2006).
The frequency of gene deletions in IHH/KS candidate genes has not
been previously reported. We hypothesized that MLPA would identify
intragenic deletions in 15–20% of IHH/KS patients. Using MLPA,
we discovered that 7.4% of 54 patients had KAL1 deletions. If only
anosmic males were considered, 4/33 (12.1%) had KAL1 deletions.
Three patients had whole gene deletions—one of which was pre-
viously described by PCR to be deleted of exons 1–13 (Bhagavath
et al., 2007). PCR and DNA sequencing subsequently conﬁrmed
a whole gene deletion in this patient. MLPA also revealed one
subject who appeared to have a deletion of exon 4. In this case,
DNA sequencing revealed a 3 bp deletion rather than an entire exon
deletion. It is likely that the probe pair did not speciﬁcally anneal to
the template of exon 4, therefore, no ligation and subsequent PCR
could be performed (Schouten et al., 2002). Our ﬁndings indicate
that putative deletions indicate identiﬁed by MLPA requires conﬁr-
mation by another technique.
We also used MLPA to screen for heterozygous intragenic deletions
of ﬁve autosomal genes—FGFR1, GNRH1, GNRHR, GPR54 and
NELF. Surprisingly, no deletions were identiﬁed in 100 IHH/KS
patients. Probe pairs were dispersed across the coding regions of
these genes, affording the opportunity to detect intragenic deletions.
Only three exons were studied for the NELF gene, but at the time
that this kit was designed, no NELF mutations had been described.
We cannot exclude that intragenic deletions of exons not included
in the kits occur, which would underestimate the prevalence of intra-
genic gene deletions. Nevertheless, no deletions of any of the ﬁve
autosomal genes were identiﬁed in 100 IHH/KS patients.
Although the prevalence of deletions in IHH/KS in autosomal genes
was much less than that expected, the prevalence of KAL1 deletions
approximated 10–15% that we hypothesized. The ﬁndings from this
pilot study demonstrate the feasibility of MLPA to detect deletions
in IHH/KS and suggest the beneﬁts of future studies with an increased
sample size of IHH/KS.
Figure 1: MLPA results demonstrating.
(A) TheKAL1exon4 deletion;(B)wholeKAL1gene deletion; (C) normalcontrol.Arrowsindicatethe deletedexons.Thehorizontal axis(top) showsthesizeof the
fragment in base pairs. A difference in relative copy peak height or peak area indicates a copy number change of the probe target sequence.
Table II. Summary of KAL1 exon/gene deletions.
Deletion type Sex Smell IHH severity Family history/comments
Whole Gene Male Anosmic Incomplete None
Whole Gene Male Hyposmic Complete Visual Field abnormality
Whole Gene Male Anosmic Complete Two ﬁrst cousins with KS
Exon 4 Male Anosmic Incomplete Renal Agenesis
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